JPMorgan Has a Neutral Outlook on Zions Bancorporation (ZION)
Zions Bancorporation, National Association (NASDAQ:ZION) is one of the new stocks David Tepper has bought.
Insider Monkey Blog
Barclays Bullish on Western Alliance Bancorporation (WAL)
Western Alliance Bancorporation (NYSE:WAL) is one of the new stocks David Tepper has bought.
Wells Fargo Has a Positive Outlook on Owens Corning (OC), Despite a Challenging Housing Market in 2026
Owens Corning (NYSE:OC) is one of the new stocks David Tepper has bought.
HoldCo Urges Comerica (CMA) Shareholders to Vote No for Potential Merger with Fifth Third Bank
Comerica Incorporated (NYSE:CMA) is one of the new stocks David Tepper has bought.
Trust Maintains a Hold Call on Citizens Financial Group (CFG), Noting Slight EPS Contraction in Banking Sector
Citizens Financial Group, Inc. (NYSE:CFG) is one of the new stocks David Tepper has bought.
Truist Maintains Hold Recommendation on KeyCorp (KEY)
KeyCorp (NYSE:KEY) is one of the new stocks David Tepper has bought.
Mizuho Analyst Bullish on Fiserv (FISV) Amid Target Adjustments in Payments and IT Names
Fiserv, Inc. (NASDAQ:FISV) is one of the new stocks David Tepper has bought.
Wells Fargo Sees Positive Drivers for American Airlines (AAL) Offset by Higher Debt
American Airlines Group Inc. (NASDAQ:AAL) is one of the new stocks David Tepper has bought.
Why These Energy Stocks are Losing This Week
2025 has been a tough year for the energy sector.
Is Advanced Micro Devices (AMD) the Best New Stock from David Tepper’s Portfolio?
Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the new stocks David Tepper has bought.
9 Stocks Jim Cramer Talked About
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the growing demand for gold, trends followed by younger people, and the US debt.
Analysts Trim Price Targets on Imperial Oil (IMO)
On December 16, TD Securities slightly lowered its price target on Imperial Oil Limited (NYSEAMERICAN:IMO) from C$107 to C$106, but maintained a ‘Sell’ rating on the shares...
TechnipFMC (FTI) Price Target Raised to $52
On December 18, Piper Sandler raised its price target on TechnipFMC plc (NYSE:FTI) from $49 to $52, representing an upside potential of over 16% from the current share price.
Innovex International (INVX) Price Target Increased by $7, ‘Overweight’ Rating Maintained
Established in 2024 following the merger of Dril-Quip and Innovex Downhole Solutions, Innovex International, Inc.
Delek US Holdings (DK) Price Target Raised as Analyst Sees ‘Underappreciated Value’
On December 12, Mizuho raised its price target on Delek US Holdings, Inc.
Sunrun (RUN) Price Target Raised Amid ‘Compelling’ Partnership with NRG Energy
On December 23, Clear Street raised its price target on Sunrun Inc. (NASDAQ:RUN) from $21 to $23, while maintaining a ‘Buy’ rating on the shares.
Par Pacific Holdings (PARR) Reveals CapEx Guidance for FY 2026
Par Pacific Holdings, Inc.
Centrus Energy (LEU) – Among the Best Performing Energy Stocks in 2025
On December 22, B. Riley analyst Ryan Pfingst significantly raised the firm’s price target on Centrus Energy Corp.
Cathie Wood’s ARK Investment Acquires Stake in OKLO
Backed by OpenAI’s Sam Altman, Oklo Inc.
Woodside Energy (WDS) Signs LNG Supply Agreement with BOTAS
The share price of Woodside Energy Group Ltd (NYSE:WDS) surged by 1.9% between December 22 and December 29, 2025, putting it among the Energy Stocks that Gained the Most This ...
North American Construction Group (NOA) Acquires Iron Mine Contracting
The share price of North American Construction Group Ltd.
Nabors Industries (NBR) Gets Double Upgrade from Analyst
The share price of Nabors Industries Ltd.
Here is Why Diversified Energy (DEC) Gained This Week
The share price of Diversified Energy Company (NYSE:DEC) surged by 2.93% between December 22 and December 29, 2025, putting it among the Energy Stocks that Gained the Most This...
Kolibri Global Energy (KGEI) Provides Operational Update on Oklahoma Field
The share price of Kolibri Global Energy Inc.
Sable Offshore (SOC) – Among the Energy Stocks that Gained This Week
The share price of Sable Offshore Corp.
Morgan Stanley Analyst Assigns Hold Rating to Truist Financial (TFC)
Truist Financial Corporation (NYSE:TFC) is one of the new stocks David Tepper has bought.
10 Best Long-Term Investments for Kids
By late 2025, long-term investing for children has evolved from simple college savings into a full “cradle-to-retirement” wealth-building ecosystem.
9 Best Auto Stocks to Buy Now
According to figures issued by the European Automobile Manufacturers' Association (ACEA) on December 23, European new car sales increased year over year in November for the fifth...
Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB)
On December 15, TheFly published that Luke Sergott, a Barclays analyst, lifted the price objective for Pacific Biosciences of California, Inc.
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)
On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price objective of $11 instead of $10.
Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP)
TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74.
Barclays Keeps Its Overweight Rating On Twist Bioscience Corporation (TWST)
TheFly reported on December 15, 2025, that Barclays kept its Overweight rating and boosted its price objective for Twist Bioscience Corporation (NASDAQ:TWST) from $37 to $39.
Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)
The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40.
Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM)
TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95.
What Do Analysts Think About GeneDx Holdings Corp. (WGS)?
TheFly reported that on December 22, 2025, GeneDx Holdings Corp. (NASDAQ:WGS) lifted its price objective at Canaccord from $160 to $170.
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE)
TheFly reports that on December 19, 2025, H.C. Wainwright upgraded Wave Life Sciences Ltd. (NASDAQ:WVE)’s price target from $22 to $30.
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene
TheFly reported on December 2, 2025, that Beam Therapeutics Inc.
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data
Prime Medicine, Inc.
20 Best Performing Dividend Stocks in 2025
2025 has felt like another strong year for stocks. The S&P 500 is up close to 18% so far.
10 Big Names Crumbling Before 2026
ASP Isotopes extended its losing streak to a third day on Tuesday, shedding 5.08 percent to close at $5.42 apiece as investors mirrored a key executive’s disposition of a significant...
10 Stocks on Fire Ahead of 2026
Meanwhile, Wall Street’s major indices all finished in the red, with the Nasdaq leading the drop by 0.24 percent, followed by the Dow Jones, down 0.20 percent, and the S&P 500...
BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View
On December 15, Bank of America raised its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $700 from $650 and kept a Buy rating on the shares.
Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market
Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market.
Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar
On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis.
BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View
On December 15, BofA lowered the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $233 from $248 and kept a Neutral rating.
FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential
On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc.
Hedge Fund Resource Center
